Get started
Author

V. Koscielny

Observed names: Koscielny, V., Koscielny, Volker, V Koscielny, V.B. Koscielny, Volker B. Koscielny, Volker Koscielny
Institution: Almirall (Spain)
ORCID: 0009-0004-3314-880X
Observed ORCID: 0009-0004-3314-880X
OpenAlex ID: A5072760779
Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
2016 · C E Collins, M Dall'Era, et al. · Lupus Science & Medicine · 128
PDF
First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
2016 · Andreas Schwarting, Johann O. Schroeder, et al. · Rheumatology and Therapy · 85
PDF
Systematic Review of the Use of the WHO-5 Well-Being Index Across Different Disease Areas
2025 · Arnau Domenech, Ismail Kasujee, et al. · Advances in Therapy · 42
PDF
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study
2020 · M. Augustin, C.E. Kleyn, et al. · Journal of the European Academy of Dermatology and Venereology · 38
PDF
Understanding remission in real-world lupus patients across five European countries
2015 · M Schneider, M Mosca, et al. · Lupus · 21
Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)
2024 · Todd Schlesinger, Leon Kircik, et al. · Journal of Drugs in Dermatology · 13
Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation
2011 · Alan G Wade, Gordon M Crawford, et al. · BMC Medical Research Methodology · 13
PDF
Phase III SUNBEAM and RADIANCE PART B Trials for Ozanimod in Relapsing Multiple Sclerosis Demonstrate Superiority Versus Interferon-β-1a (Avonex ® ) in Reducing Annualized Relapse Rates and MRI Brain Lesions
2018 · Volker Koscielny · Neurodegenerative Disease Management · 11
PDF
OP0048 Outcomes in Systemic Lupus Erythematous (SLE) Patients Treated with Belimumab in Clinical Practice Settings: Results from the Observe Study in Germany
2014 · A. Schwarting, V.B. Koscielny, et al. · Annals of the Rheumatic Diseases · 8
Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study)
2023 · Todd Schlesinger, Leon Kircik, et al. · SKIN The Journal of Cutaneous Medicine · 6
PDF
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
2025 · Matthias Augustin, Anthony Bewley, et al. · BMJ Open · 5
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study
2025 · Ulrich Mrowietz, Rachel Sommer, et al. · Psoriasis Targets and Therapy · 3
PDF
Patient- and clinician-reported outcomes of calcipotriol/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, noninterventional, multicentre PRO-SCALP study
2026 · Jose Luis López Estebaranz, Anthony Bewley, et al. · Clinical and Experimental Dermatology · 2
Patient and Clinician‐Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD‐Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO‐SCALP Study
2025 · Andreas Pinter, Jose Luis López Estebaranz, et al. · JEADV Clinical Practice · 2
PDF
Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study
2026 · Anthony Bewley, Andreas Pinter, et al. · Dermatology and Therapy · 1
PDF
Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)
2023 · Leon Kircik, Todd Schlesinger, et al. · SKIN The Journal of Cutaneous Medicine · 1
PDF
Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)
2023 · Todd Schlesinger, Leon Kircik, et al. · SKIN The Journal of Cutaneous Medicine · 1
PDF
Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: PROSES study analysis by gender and age
2023 · Emmy Graber, Hilary Baldwin, et al. · SKIN The Journal of Cutaneous Medicine · 1
PDF
Pss74 - Patient Quality of Life and Satisfaction in an Apremilast-treated Psoriasis Population: Analysis of 126 Patients From the Appreciate Study in the United Kingdom and Ireland
2018 · L. Yeo, K. Shams, et al. · Value in Health · 1
Real-world experience with apremilast in patients with psoriasis: interim analysis of 104 patients from the APPRECIATE study
2017 · Kleyn, E., Radtke, M., et al. · ORCA Online Research @Cardiff (Cardiff University) · 1
FRI0374 Outcomes in Systemic Lupus Erythematosus Patients with High Disease Activity Treated with Belimumab: 18 Month Results from the US Observe Study
2014 · C.E. Collins, M. Dall'Era, et al. · Annals of the Rheumatic Diseases · 1
THU0261 Outcomes in Systemic Lupus Erythematous (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S.)
2013 · H. Kan, C. Collins, et al. · Annals of the Rheumatic Diseases · 1
75192 Beyond skin clearance: Tildrakizumab improves high burdensome symptoms and psychological well-being in moderate-to-severe psoriasis patients – 2-year POSITIVE study results
2026 · Ulrich Mrowietz, Rachel Sommer, et al. · Journal of the American Academy of Dermatology
71092 Sustained effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas: 2-year results from the POSITIVE study
2026 · Matthias Augustin, Rachel Sommer, et al. · Journal of the American Academy of Dermatology
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
2026 · Ulrich Mrowietz, Rachel Sommer, et al. · Psoriasis Targets and Therapy
PDF
Works count: 52
Citation count: 385
H-index: 8
I10-index: 8
Year
Topic
Type